GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aethlon Medical Inc (NAS:AEMD) » Definitions » Beneish M-Score
中文

Aethlon Medical (Aethlon Medical) Beneish M-Score

: 35.54 (As of Today)
View and export this data going back to 1999. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 35.54 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Aethlon Medical's Beneish M-Score or its related term are showing as below:

AEMD' s Beneish M-Score Range Over the Past 10 Years
Min: -29.13   Med: -3.14   Max: 35.54
Current: 35.54

During the past 13 years, the highest Beneish M-Score of Aethlon Medical was 35.54. The lowest was -29.13. And the median was -3.14.


Aethlon Medical Beneish M-Score Historical Data

The historical data trend for Aethlon Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aethlon Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.37 -0.10 -3.15 -2.67 -2.84

Aethlon Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.03 -2.84 -1.68 12.49 35.54

Competitive Comparison

For the Medical Devices subindustry, Aethlon Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aethlon Medical Beneish M-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aethlon Medical's Beneish M-Score falls into.



Aethlon Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aethlon Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 2.0019+0.892 * 44.1538+0.115 * 0.4907
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.0226+4.679 * -0.166523-0.327 * 1.6289
=35.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0.574 = $0.57 Mil.
Gross Profit was 0 + 0 + 0 + 0.574 = $0.57 Mil.
Total Current Assets was $8.25 Mil.
Total Assets was $10.44 Mil.
Property, Plant and Equipment(Net PPE) was $2.07 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.35 Mil.
Selling, General, & Admin. Expense(SGA) was $13.20 Mil.
Total Current Liabilities was $2.10 Mil.
Long-Term Debt & Capital Lease Obligation was $0.73 Mil.
Net Income was -3.466 + -3.034 + -3.282 + -2.467 = $-12.25 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -2.378 + -2.704 + -2.482 + -2.947 = $-10.51 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0.013 = $0.01 Mil.
Gross Profit was 0 + 0 + 0 + 0.013 = $0.01 Mil.
Total Current Assets was $18.17 Mil.
Total Assets was $20.72 Mil.
Property, Plant and Equipment(Net PPE) was $2.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.19 Mil.
Selling, General, & Admin. Expense(SGA) was $13.22 Mil.
Total Current Liabilities was $2.44 Mil.
Long-Term Debt & Capital Lease Obligation was $1.01 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.574) / (0 / 0.013)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.013 / 0.013) / (0.574 / 0.574)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8.249 + 2.065) / 10.437) / (1 - (18.172 + 2.43) / 20.724)
=0.011785 / 0.005887
=2.0019

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.574 / 0.013
=44.1538

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.187 / (0.187 + 2.43)) / (0.352 / (0.352 + 2.065))
=0.071456 / 0.145635
=0.4907

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(13.202 / 0.574) / (13.22 / 0.013)
=23 / 1016.923077
=0.0226

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.725 + 2.101) / 10.437) / ((1.009 + 2.436) / 20.724)
=0.270767 / 0.166232
=1.6289

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-12.249 - 0 - -10.511) / 10.437
=-0.166523

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aethlon Medical has a M-score of 35.54 signals that the company is likely to be a manipulator.


Aethlon Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Aethlon Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aethlon Medical (Aethlon Medical) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Executives
Nicolas Gikakis director 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO CA 92121
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Angela Rossetti director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Steven P Larosa officer: Chief Medical Officer 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA 92123
Chetan Shah director 9 GRACE HILL COURT, TITUSVILLE NJ 08560
Fisher Charles J Jr director C/O AETHLON MEDICAL, INC., 9635 GRANITE RIDGE DR., SUITE 100, SAN DIEGO CA 92123
Guy F. Cipriani director 1727 EAGLERIDGE DRIVE, BELLINGHAM WA 98226
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Rodell Timothy C Jr officer: Interim CEO 201 MIDLAND AVE, ASPEN CO 81611
Weiner Family Revocable Trust Ellen R. 10 percent owner 10645 N. TATUM BOULEVARD, SUITE 200-166, PHOENIX AZ 85028
Phillip A Ward director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Thomas V Wornham director 8910 UNIVERSITY CENTER LANE #660, SAN DIEGO CA 92122
Rodney S Kenley director, officer: President 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
James B Frakes officer: Chief Financial Officer 9635 GRANITE RIDGE DRIVE, SUITE 100, SAN DIEGO CA 92123
Barry Franklyn S Jr director 1141 DELAWARE AVENUE #3N, BUFFALO NY 14209